Graft Polymer's Alex Brooks joined Proactive London to talk about its first commercial purchase order for GraftBio - its new division founded in 2020 to develop intellectual property for pharma applications.
Graft Polymer said it will begin production immediately on the US$1mln order for an anti-inflammatory supplement that will be sold in the US market.
Brooks says its speciality is bonding one material to another with a focus on grafting, a technique for joining two otherwise incompatible polymers.